TIAM2 functional gene mutation has no effect of on bleeding events after clopidogrel antiplatelet therapy in patients with coronary heart disease
10.3969/j.issn.1006-5725.2014.07.022
- VernacularTitle:TIAM2功能性基因突变对冠心病患者氯吡格雷抗血小板治疗后出血事件的影响
- Author:
Xinxin LI
;
Shilong ZHONG
;
Yuan LI
;
Suhui WEI
;
Mengzhen ZHANG
;
Zhoucuo QI
;
Jiyan CHEN
;
Haiyan LAO
- Publication Type:Journal Article
- Keywords:
Coronary disease;
TIAM2 gene;
Clopidogrel;
Bleeding events
- From:
The Journal of Practical Medicine
2014;(7):1080-1083
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the correlation of the TIAM2 functional gene mutations with the bleeding events in patients with coronary heart disease who undergone PCI and postoperative taken anti-platelet drug clopi-dogrel. Methods One hundred and twenty Chinese Han patients who had undergone PCI and postoperative taken anti-platelet drug clopidogrel were orderly enrolled from Guangdong General Hospital. Followed for 6 months after PCI, PCR sequencing was applied to test TIAM2 promoter region genotyping assay. Results After follow-up six months , 113 cases were remained lost of 7 cases , , including 19 cases with bleeding and 94 cases without bleed-ing; Bleeding risk in patients with diabetes mellitus (OR=3.115) or taking statins (OR=11.539), may be high, but there was no significant difference (P > 0.05); TIAM2 promoter region had three variants (c.3168+3116C>T, c.3168+3261A>G,c.3168+3596A>C), including wild-type, heterozygous, and homozygous. The probability of pa-tients with bleeding were 36.84%, 52.63%and 10.53%, and there is a certain chain of state , but the genotype was not significantly correlated with bleeding events of clopidogrel antiplatelet therapy (P>0.05). Conclusion Clopi-dogrel antiplatelet therapy bleeding events were not significantly correlated with TIAM2 functional gene mutation.
